Holen Sie sich die Stockscreener-App
10.39
5.80%
-0.64
Kailera Therapeutics Inc Aktie (KLRA) Neueste Nachrichten
Kailera Therapeutics (NASDAQ:KLRA) Stock Falls 5.6%Should You Sell? - MarketBeat
Kailera presents phase 1 data for ribupatide at EASD meeting - Investing.com
An obesity shot showed similar drug levels after injection in the arm, thigh or abdomen. - Stock Titan
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy - theglobeandmail.com
KLRA: Ribupatide leads a diverse obesity pipeline with pivotal data expected in 2027–2028 - TradingView
Kailera Therapeutics (KLRA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $KLRA - MarketBeat
Kailera completes enrollment in phase 3 obesity drug trials - Investing.com
Kailera Therapeutics Completes Enrollment for Trial of Ribupatide to Treat Obesity - marketscreener.com
Three trials of a weekly obesity shot have finished enrolling; results are expected in mid-2028. - Stock Titan
Kailera Therapeutics (NASDAQ:KLRA) Hits New 12-Month LowHere's Why - MarketBeat
868,160 Shares of Kailera Therapeutics, Inc. $KLRA Acquired by State Street Corp - MarketBeat
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
KLRA: Differentiated GLP-1 assets and strategy position the company for growth in the expanding obesity market - TradingView
Kailera at bernstein healthcare forum: betting on obesity differentiation By Investing.com - Investing.com Canada
Kailera at bernstein healthcare forum: betting on obesity differentiation - Investing.com
Kailera Therapeutics (NASDAQ:KLRA) Reaches New 12-Month LowWhat's Next? - MarketBeat
Weight-loss drug developers line up to tap lucrative market as competition heats up - Reuters
Kailera Therapeutics (NASDAQ:KLRA) Shares Down 5.5%Time to Sell? - MarketBeat
Kailera Therapeutics, Inc.(NasdaqGS:KLRA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to S&P Global BMI Index - marketscreener.com
Kailera Therapeutics: Hold Due To Need For Progress On Weight Loss Differentiation (KLRA) - Seeking Alpha
Kailera Therapeutics targets obesity with GLP-1 drug, raising $718M in IPO despite 40% share drop. - Pluang
Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval - Seeking Alpha
Kailera Therapeutics to Participate in September Investor Conferences - The Manila Times
Kailera Therapeutics to Participate in Upcoming Investor Conferences - Quiver Quantitative
Kailera Therapeutics (NASDAQ:KLRA) Hits New 52-Week LowTime to Sell? - MarketBeat
Jim Cramer Calls Kailera Therapeutics (KLRA) “The Most Speculative Stock On Earth” - finance.yahoo.com
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Sets New 52-Week LowWhat's Next? - MarketBeat
Kailera Therapeutics (KLRA) grants CTO 220,000 stock options - Stock Titan
Kailera Therapeutics (KLRA) CTO reports no shares in first ownership filing - Stock Titan
Kailera Therapeutics (NASDAQ:KLRA) Shares Down 7%Should You Sell? - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Frazier Life Sciences Management L.P. Acquires Shares of 1,100,000 Kailera Therapeutics, Inc. $KLRA - MarketBeat
Atlas Venture Life Science Advisors LLC Makes New Investment in Kailera Therapeutics, Inc. $KLRA - MarketBeat
2,919,110 Shares in Kailera Therapeutics, Inc. $KLRA Acquired by Wellington Management Group LLP - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Trading Up 7.9%Here's Why - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Reaches New 1-Year LowShould You Sell? - MarketBeat
Kailera Stock Falls 12.5%, Leaving Market Value Just $930 Million Above Cash - ts2.tech
Kailera Therapeutics (NASDAQ:KLRA) Trading Down 8.6%Should You Sell? - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Trading 8.6% HigherHere's Why - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Hits New 1-Year LowHere's Why - MarketBeat
2 GLP-1 Stocks That Could Double Your Money by 2031 - AOL.com
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - mexc.co
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Hengrui Pharma's Innovative Drug Revenue Share Tops 60% in H1; Two NewCo Partners List on Nasdaq - finance.biggo.com
KLRA Archives - 24/7 Wall St.
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More - AOL.com
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore - 24/7 Wall St.
Kailera Therapeutics (NASDAQ:KLRA) Trading 6.6% HigherHere's Why - MarketBeat
Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified? - Yahoo Finance
Canada Pension Plan (KLRA) discloses 5.6% Kailera Therapeutics ownership in 13G filing - Stock Titan
Jefferies Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):